Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,417 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Parkinson´s Disease Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

A Mobile Application for Telerehabilitation in Parkinson's Disease

NCT03459586
View directory record Official record
Conditions
Parkinson Disease
Interventions
9zest app facilitated exercise
Other
Lead sponsor
9zest. Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 10, 2026, 1:51 AM EDT
Enrolling by invitation Phase 4 Interventional

Quality Improvement and Practice Based Research in Neurology Using the EMR

NCT02670161
View directory record Official record
Conditions
Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
Interventions
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 100 Years
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 10, 2026, 1:51 AM EDT
Terminated Not applicable Interventional

SMARTfit Training for Parkinson's Disease

NCT03921359
View directory record Official record
Conditions
Parkinson Disease, Exercise Training, Cognitive Change
Interventions
SMARTfit training, Conventional physical training
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
50 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 10, 2026, 1:51 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

NCT03185481
View directory record Official record
Conditions
Parkinson's Disease With Motor Fluctuations
Interventions
1 mg QD to 15 mg QD PF-06649751, 3 mg QD to 15 mg QD PF-06649751, 7 mg QD to 15 mg QD PF-06649751, 15 mg QD PF-06649751, 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study), 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study), 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study), 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 87 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
9
States / cities
Newport Beach, California • Fairfield, Connecticut • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 10, 2026, 1:51 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

NCT04396873
View directory record Official record
Conditions
Parkinson's Disease, Dementia, Alzheimer's Disease, ALS, Mild Cognitive Impairment
Interventions
11C-MC1, 11C-PS13, 18f-florbetaben
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 99 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 10, 2026, 1:51 AM EDT
Completed Phase 2 Interventional

Phase 2a Study of VTX3232 in Parkinson's Disease

NCT06556173
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
VTX3232
Drug
Lead sponsor
Zomagen Biosciences Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 10, 2026, 1:51 AM EDT
Completed No phase listed Observational Results available

Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD

NCT03647137
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Detailed motor testing, including FoG, in PD subjects
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 10, 2026, 1:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Frontal Cortex and Gait Freezing in Parkinson's Disease: Rehabilitation Impact

NCT02236286
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Exercise
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 10, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

NCT03713957
View directory record Official record
Conditions
Parkinson Disease
Interventions
GRF6021, Placebo
Drug · Other
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Englewood, Colorado • Doral, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 10, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease

NCT03000569
View directory record Official record
Conditions
Parkinson Disease
Interventions
SAGE-217, Levodopa, Antiparkinsonian Agent(s)
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Panorama City, California • Jacksonville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 10, 2026, 1:51 AM EDT
Completed Not applicable Interventional

More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease

NCT03076671
View directory record Official record
Conditions
Parkinson Disease, Parkinsonism, Lewy Body Disease, Supranuclear Palsy, Progressive, Parkinsonism Vascular, Multiple System Atrophy, Corticobasal Degeneration, Alzheimer Disease, Frontotemporal Dementia, Primary Progressive Aphasia, Vascular Dementia
Interventions
Palliative Care
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 105 Years
Enrollment
783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
San Francisco, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 10, 2026, 1:51 AM EDT
Completed Phase 4 Interventional Results available

Cognitive Decline in Non-demented PD

NCT01340885
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Strattera, Exelon, Placebo
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 10, 2026, 1:51 AM EDT
Completed Not applicable Interventional

The Use of Telerehabilitation to Improve Movement Outcomes for Patients With Parkinson Disease

NCT06246747
View directory record Official record
Conditions
Parkinson Disease
Interventions
In clinic physical therapy, Telerehabilitation only
Other
Lead sponsor
Wizecare
Industry
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 10, 2026, 1:51 AM EDT
Completed Phase 2 Interventional

Study of LY300164 for the Treatment of Parkinson's Disease

NCT00004576
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease
Interventions
LY300164
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 10, 2026, 1:51 AM EDT
Completed Phase 1 Interventional

Study of the Fecal Microbiome in Patients With Parkinson's Disease

NCT03671785
View directory record Official record
Conditions
Parkinson Disease
Interventions
PRIM-DJ2727, Placebo oral capsule
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
55 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 10, 2026, 1:51 AM EDT
Recruiting No phase listed Observational

Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

NCT07642908
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
45 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 10, 2026, 1:51 AM EDT
Completed No phase listed Observational Results available

Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)

NCT03944785
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
XADAGO (safinamide)
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
30
States / cities
Homewood, Alabama • Bakersfield, California • Laguna Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 10, 2026, 1:51 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease

NCT07020026
View directory record Official record
Conditions
Parkinson's Disease
Interventions
[18F]PI-2620
Drug
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
45 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 10, 2026, 1:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease

NCT01155492
View directory record Official record
Conditions
Parkinson's Disease, Multiple System Atrophy
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
25 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 10, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

NCT01653132
View directory record Official record
Conditions
Sialorrhea
Interventions
Incobotulinum Toxin A, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 10, 2026, 1:51 AM EDT
Completed Not applicable Interventional

Periodization and Parkinson's Disease

NCT07141849
View directory record Official record
Conditions
Activity, Motor
Interventions
Power Resistance Training, Periodized Resistance Training
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
50 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 10, 2026, 1:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Connect.Parkinson: Connecting Individuals With Parkinson Disease to Specialists in Their Homes

NCT02038959
View directory record Official record
Conditions
Parkinson Disease
Interventions
Virtual Visits
Other
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
20
States / cities
San Francisco, California • Sunnyvale, California • Gainsville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 10, 2026, 1:51 AM EDT
Recruiting Not applicable Interventional

Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD

NCT06883266
View directory record Official record
Conditions
Parkinsons Disease (PD)
Interventions
transcranial direct current stimulation (tDCS), Sham (No Treatment)
Device
Lead sponsor
Sanford Health
Other
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 10, 2026, 1:51 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Multidisciplinary Lifestyle Interventions for Neurological Disorders During the Silent Phase

NCT05984056
View directory record Official record
Conditions
Neurological Disorder
Interventions
Multidisciplinary lifestyle interventions
Behavioral
Lead sponsor
Vineet Punia MD
Other
Eligibility
50 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2036
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 10, 2026, 1:51 AM EDT